AbbVie Ventures

Enthera Pharmaceuticals adds Margarita Chavez to its Board along with raising €28m Series A financing co-led by Sofinnova Partners and AbbVie Ventures

– ITALY, Milan –  Enthera Pharmaceuticals, a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announced the completion of a €28 million Series A financing round co-led by seed investor Sofinnova Partners, and incoming investor AbbVie Ventures, with further investment from the JDRF T1D Fund and several Italian investors including a group coordinated by Banor SIM, a group coordinated by Banca Profilo through Arepo Fiduciaria and Indaco Venture Partners SGR.…

Nitrome Biosciences strengthens its Board along with raising $38m Series A financing co-led by Sofinnova Partners and AbbVie Ventures

– USA, CA –  Nitrome Biosciences, a privately-held biopharmaceutical company developing a platform around a newly identified class of enzymes to target Parkinson’s disease and other age-related disorders, today announced that it has closed a Series A financing of $38 million co-led by Sofinnova Partners and AbbVie Ventures, with further participation from the Dementia Discovery Fund, Mission Bay Capital and Alexandria Venture Investments.…